Expert Discusses Optimizing CDK 4/6 Inhibitors in Breast Cancer

Expert Discusses Optimizing CDK 4/6 Inhibitors in Breast Cancer

2018-03-29 00:19:00

Reshma Mahtani, DO, discusses the tolerability of CDK 4/6 inhibitors for the treatment of patients with metastatic breast cancer.

Source

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply